For the Quarter Ending June 2025
North America
• The Amlodipine Besylate Spot Price in the U.S. increased marginally in April (+0.25%), dropped sharply in May (-2.77%), and rebounded slightly in June (+0.64%), with the Price Index reaching USD 70,360/MT (CFR Los Angeles) by the end of Q2.
• April’s increase was primarily driven by a rush in API procurement due to the 145% U.S. tariff on Chinese goods, encouraging buyers to frontload orders and stockpile inventories ahead of expected cost hikes.
• Strong importer demand and rerouted logistics contributed to tighter supply and a firm Amlodipine Besylate Demand Outlook, even as the inflation backdrop remained surprisingly soft.
• In May, price levels fell sharply as buyers paused purchasing to reassess inventory levels and pricing after a 90-day trade truce and partial rollback of some tariffs were announced mid-month.
• A significant regulatory development in May—the introduction of the “Most Favored Nation” pricing policy—created hesitation, compelling buyers to delay restocking and reducing procurement activity.
• In June, prices edged up as companies resumed imports to pre-empt any tariff escalation post-truce. Forward purchasing increased, especially from formulators aiming to lock in prices for H2 2025.
• Logistics operated efficiently throughout Q2, allowing pre-truce procurement strategies to play out with minimal delays across U.S. ports.
• The Amlodipine Besylate Price Forecast for early Q3 suggests stability with slight downside potential if trade clarity improves and inventory stock remains high.
• July 2025 prices likely declined modestly, influenced by reduced urgency in buying, improved confidence in stable U.S.–China trade ties, and full warehouses from aggressive Q2 stocking.
APAC
• The Amlodipine Besylate Spot Price in China witnessed a marginal increase in April (+0.28%) and June (+0.53%), while May saw a significant decline of -2.79%, reflecting mixed fundamentals across the quarter.
• In April, the Price Index rose to USD 71,800/MT (FOB Shanghai) as pre-tariff frontloading in global markets, particularly the U.S., supported export demand and tightened Chinese availability.
• The Amlodipine Besylate Demand Outlook from international buyers remained firm in April, especially due to the impending U.S. tariff, which pushed exporters to raise prices slightly amid logistical adjustments.
• A sharp price correction occurred in May as frontloaded orders tapered and domestic suppliers responded with lower quotations amidst reduced international offtake and improving inventories.
• In June, the Price Index edged up by 0.53% to USD 70,170/MT, driven by proactive reordering from overseas buyers ahead of any further geopolitical shifts and mild recovery in global API demand.
• The Amlodipine Besylate Production Cost Trend in China remained stable throughout Q2, with raw material costs and energy inputs showing no major fluctuations.
• Improved shipping schedules and stable inland logistics allowed for smooth cargo movement in May–June, preventing any bottlenecks despite external policy concerns.
• By quarter-end, Chinese exporters held relatively manageable inventories, although order visibility for Q3 remained moderate amid rising competition from alternate API suppliers in India and Southeast Asia.
• The Amlodipine Besylate Price Forecast for July suggested slight pressure on prices due to softened global offtake and elevated post-truce inventories.
• July 2025 prices likely decreased marginally in China as frontloaded Q2 shipments and easing export orders led to restrained spot quotations across key trade hubs.
Europe
• The Amlodipine Besylate Spot Price in Germany mirrored global trends with a slight rise in April (+0.29%), a dip in May (-2.80%), and a mild rebound in June (+0.57%) to reach USD 70,280/MT (CFR Hamburg).
• April’s gains were supported by elevated global demand and pre-emptive ordering by European pharmaceutical distributors who responded to cost uncertainty linked to U.S.–China tariffs.
• The Amlodipine Besylate Demand Outlook in Germany remained stable through April as formulators actively participated in global procurement cycles to ensure continuity of supply amid global trade dislocation.
• May recorded the steepest monthly decline as improved availability from Asia and reduced downstream urgency led to inventory normalization and price corrections.
• The Amlodipine Besylate Production Cost Trend in Europe remained steady throughout Q2, with most cost changes driven by imported material prices rather than local processing.
• June saw a rebound in prices due to anticipated supply constraints in Q3 and proactive import activity by European distributors hedging against external disruptions.
• As with the U.S., many German buyers advanced their procurement timelines to mitigate future volatility, leading to early demand bunching in late Q2.
• Port operations and container logistics across North Europe ran smoothly, enabling timely delivery of forward-booked cargoes from Asia.
• The Amlodipine Besylate Price Forecast for early Q3 indicates possible softening, given excess inventories and a weaker-than-usual restocking pattern from smaller distributors.
• July 2025 prices likely decline due to the combination of high stock levels, eased pressure from Asian exporters, and conservative procurement across the EU pharmaceutical sector.
For the Quarter Ending March 2025
North America
During Q1 2025, Amlodipine Besylate prices in the U.S. experienced fluctuating trends shaped by trade policy shifts, supply chain dynamics, and varying demand. In January, prices moderately increased as importers rushed to secure shipments ahead of the proposed 10% tariff on Chinese goods set for February. This surge in procurement, compounded by the upcoming Chinese Lunar New Year and rising energy costs, strained supply chains and elevated prices. Port congestion in Los Angeles, worsened by wildfire-related disruptions, further delayed shipments and pushed operational costs higher.
However, February saw a decline in prices due to improved Chinese production after the holiday and reduced transpacific freight rates, enhancing supply flow into the U.S. Demand weakened as economic uncertainty and prior stockpiling discouraged fresh purchases. By March, prices rose slightly amid renewed buying activity, as President Trump’s March 4 tariff actions on major trading partners reignited concerns over pharmaceutical supply disruptions. With more tariffs anticipated in April, market participants frontloaded procurement. Eased consumer inflation slightly improved sentiment, adding to the firming trend.
Overall, Q1 reflected a volatile but resilient pricing environment, driven by geopolitical and logistical factors.
Asia Pacific
In Q1 2025, the Amlodipine Besylate market in China saw notable price fluctuations driven by shifting supply and demand dynamics. In January, prices increased due to rising demand from the pharmaceutical and healthcare sectors, along with supply constraints caused by the Lunar New Year holiday, which reduced manufacturing output. Additionally, exporters rushed to frontload shipments ahead of anticipated U.S. tariffs, tightening supply and fueling bullish market sentiment. In February, prices slightly declined as supply stabilized. Manufacturing activity improved post-holiday, boosting production capacity, while demand remained weak due to deflationary pressures, limited consumer spending, and sluggish activity in the pharmaceutical sector. The impact of U.S. tariffs also led to higher domestic inventories as exporters shifted focus to local markets. By March, prices increased modestly as supply struggled to meet sustained demand. Low inventory levels, accelerated procurement from foreign buyers due to trade uncertainties, and stronger domestic demand, driven by fiscal stimulus and restocking before plant maintenance, all contributed to tightening market conditions. Overall, the quarter saw a moderate price increase, influenced by varying supply constraints and demand shifts.
Europe
In Q1 2025, Amlodipine Besylate prices in Germany saw significant fluctuations driven by a mix of demand, supply conditions, and external factors. January experienced a moderate price increase, bolstered by an improvement in German business morale and favorable monetary policy, which boosted demand from the healthcare and pharmaceutical sectors. Early stockpiling due to supply chain delays caused by the Lunar New Year further pressured prices upwards. However, February saw a price decline, as ample supply and weak demand resulted in less urgency for new orders. The appreciation of the Euro against the US Dollar and a sharp drop in freight rates allowed for cost-effective imports, leading to an inventory buildup. In contrast, March saw prices rise again as supply constraints intensified, driven by port congestion and labor unrest across Europe, affecting shipments. Restocking activity resumed, and increased confidence in the pharmaceutical sector fueled demand, leading to a price recovery. By the end of Q1, Amlodipine Besylate prices had shown a moderate upward trend, with a stronger outlook for the coming months.
For the Quarter Ending December 2024
North America
During Q4 2024, Amlodipine Besylate prices in the USA exhibited dynamic shifts, driven by evolving market conditions. Prices surged in October due to heightened demand, fueled by Federal Reserve rate cuts that bolstered consumer confidence. Prolonged port congestion, labor strikes, and fears of tariff hikes under President-elect Donald Trump disrupted supply chains, exacerbating supply-demand imbalances and driving prices upward.
In November, prices slightly declined as demand softened amidst inflationary pressures and high interest rates. The appreciation of the U.S. dollar reduced import costs, while the resolution of the ILA strike eased logistics. These factors, combined with healthy inventories, allowed suppliers to lower prices, passing on savings to consumers.
By December, Amlodipine Besylate prices fell further due to dampened consumer confidence, seasonal demand slowdowns, and proactive inventory buildup ahead of potential January strikes and the Chinese Lunar New Year. Inflation concerns and tariff uncertainties prompted cautious buying, while ample supply and competitive pricing strategies added downward pressure. Overall, Q4 showcased a volatile market that ultimately trended downward. As of the end of Q4, Amlodipine Besylate was priced at USD 72,800 per metric ton (USP, FDA) CFR Los Angeles.
Asia Pacific
In Q4 2024, the Amlodipine Besylate market in China showcased a dynamic pricing trend influenced by varying economic and market factors. In October, prices rose significantly, driven by the resurgence of China's manufacturing sector following government stimulus measures. Increased domestic and export demand, coupled with monetary easing and a depreciated yuan, bolstered consumer confidence and external orders, enabling suppliers to raise prices.
However, this upward momentum reversed in November as high inventory levels, slowing domestic demand, and weak international orders, particularly from the USA and Europe, led to oversupply and cautious market sentiment. Falling crude oil prices further reduced operational costs, prompting manufacturers to lower prices to remain competitive.
In December, prices declined further due to subdued consumer demand amid China’s ongoing disinflation. Pharmaceutical companies and international buyers adjusted procurement strategies, contributing to weaker demand. Additionally, reduced foreign orders during the holiday season left suppliers with excess stock, forcing price cuts to clear inventories before year-end. Overall, Q4 reflected a shift from price gains in October to declines in the subsequent months due to fluctuating demand and market conditions. By the end of Q4, Amlodipine Besylate was priced at USD 70800 per metric ton in China.
Europe
In Q4 2024, Amlodipine Besylate prices in Germany exhibited contrasting trends across the months. October saw a significant price increase driven by improved business morale, bolstered by optimism around economic recovery and the European Central Bank’s third interest rate cut to 3.25%. This policy spurred spending and investment, while preemptive inventory buildup and supply chain challenges, including delays at Hamburg’s ports, added upward pressure.
However, November marked a downturn as weak end-sector demand and fading inflation concerns subdued price pressures. A sharp decline in consumer spending and retail performance in Germany, coupled with a 1.9% drop in energy prices, reduced operational costs and allowed suppliers to offer competitive rates.
The downward trend persisted into December due to weak demand from key sectors, cautious buyer behavior amid inflation concerns, and increased import costs due to the euro’s depreciation. Ample inventories and year-end stock clearance efforts further weighed on prices, while harsh winter conditions slowed consumer activity and logistics, exacerbating the decline. Overall, Q4 reflected a shift from initial optimism to economic caution, impacting price dynamics. By the end of Q4, Amlodipine Besylate was priced at USD 72610 per metric ton (USP, FDA) CFR Hamburg.
For the Quarter Ending September 2024
North America
During Q3 2024, the pricing landscape for Amlodipine Besylate in North America exhibited remarkable stability, marked by consistent market conditions throughout the quarter. Several key factors contributed to this stability, including steady demand from end-users and stable supply levels, resulting in a well-balanced equilibrium between supply and demand dynamics.
In the USA, where the most significant price fluctuations occurred, market trends reflected the broader North American environment. While the quarter recorded a slight percentage decrease in prices compared to the previous quarter, this adjustment was minor and did not indicate any drastic changes. Furthermore, a comparison between the first and second halves of the quarter revealed no substantial price variance, underscoring a period characterized by relative price stability.
As Q3 2024 drew to a close, Amlodipine Besylate was priced at USD 72,985 per metric ton (USP, FDA) CFR Los Angeles. This final price underscored the market's neutral position, reflecting a period where prices remained relatively stable throughout the quarter. Such consistency reinforces the overall trend of stability in the pricing environment for this pharmaceutical product, indicating a balanced interplay of supply and demand without significant fluctuations.
Asia Pacific
In Q3 2024, the APAC region witnessed a pronounced upward trend in Amlodipine Besylate prices, influenced by several key factors. Strong global demand, particularly from major markets, led to heightened precautionary orders, driving prices higher. Compounding this were supply chain disruptions, notably exacerbated by extreme weather events, which constrained supply levels and further fueled price increases. Despite facing challenges such as geopolitical uncertainties and the impact of tariffs, the market maintained a positive sentiment, buoyed by robust demand and favorable supply dynamics. China, in particular, experienced the most significant price fluctuations, mirroring broader trends across the region. The quarter highlighted a consistent upward movement in prices, with a notable 1% increase from the first half to the second half of the quarter. By the end of Q3 2024, Amlodipine Besylate was priced at USD 70,900 per metric ton in China, emphasizing the steady growth trajectory. Market participants actively focused on inventory management strategies to navigate these evolving market conditions. Overall, the quarter showcased a resilient market for Amlodipine Besylate in the APAC region, characterized by strong demand and effective supply management amidst various challenges.
Europe
In Q3 2024, the pricing trend for Amlodipine Besylate in Europe displayed a marked increase, particularly in Germany, where the most significant price changes occurred. Several critical factors contributed to this upward movement in market prices. Firstly, sustained high demand from end-users, along with improving economic conditions and declining inflation rates, created a solid foundation for price growth. Additionally, disruptions in shipping routes, especially due to the ongoing Red Sea crisis, prompted retailers to expedite their inventory replenishment, further fueling price increases. This environment fostered a positive market sentiment, with buyers increasing their purchasing activities to secure adequate inventory levels. While there was a slight decline in prices compared to the previous quarter, the overall trend for the quarter showed a 1% increase in prices from the first half to the second half. By the end of Q3 2024, Amlodipine Besylate was priced at USD 72,725 per metric ton (USP, FDA) CFR Hamburg in Germany, underscoring the upward trajectory in pricing during this period. Overall, the quarter illustrated a robust market for Amlodipine Besylate in Europe, driven by strong demand and proactive inventory management amidst various challenges.
FAQs
Q1. What is the current price of Amlodipine Besylate across key regions?
As of June 2025, the Amlodipine Besylate Spot Price stood at USD 70,170/MT FOB Shanghai in China, USD 70,360/MT CFR Los Angeles in the United States, and USD 70,280/MT CFR Hamburg in Germany. These prices reflect a modest recovery from the sharp drop observed in May, supported by anticipatory restocking and proactive procurement amid lingering trade policy uncertainties.
Q2. Why did Amlodipine Besylate prices drop significantly in May 2025?
The sharp price correction in May—approximately -2.8% across all three regions—was primarily driven by a cautious market environment. Buyers slowed down procurement following heavy frontloading in April and paused new orders to reassess strategies after a temporary 90-day truce was declared in the U.S.–China tariff standoff. Additionally, a new U.S. executive order announced on May 12 introduced steep price benchmarking policies for prescription drugs, which added further hesitation to the market.
Q3. What led to the partial rebound in Amlodipine Besylate prices during June 2025?
Prices increased modestly in June as pharmaceutical importers, especially in the United States and Germany, resumed forward purchases during the tariff pause. This behavior was influenced by fears of future cost escalations, leading buyers to accelerate shipments and lock in supply ahead of potential policy changes. Even though the production cost trend remained steady, the anticipation of renewed trade disruptions in Q3 added upward pressure on the price index.
Q4. Did Amlodipine Besylate prices increase or decrease in July 2025, and why?
Amlodipine Besylate prices most likely decreased in July 2025 across all regions. This was due to a combination of elevated inventory levels carried over from Q2, stabilized export availability from China, and reduced urgency among buyers following the conclusion of frontloaded purchases. With supply chains functioning smoothly and demand returning to routine levels, the spot price softened in response to surplus stock and a more relaxed procurement sentiment.
